Drug Interaction Report

GENERALLY AVOID: Coadministration with capmatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of CYP450 1A2. The proposed mechanism is decreased clearance due to capmatinib-mediated inhibition of CYP450 1A2 isoenzyme. Coadministration with capmatinib increased the systemic exposure (AUC0-INF) of caffeine (a CYP450 1A2 substrate) by 134%, but did not affect the peak plasma concentration (Cmax) of caffeine.

MANAGEMENT: Coadministration of capmatinib with drugs that are substrates of CYP450 1A2 should generally be avoided. However, if concomitant use is unavoidable, caution is advised, particularly with drugs that have a narrow therapeutic range. Clinical and laboratory monitoring should be considered whenever capmatinib is added to or withdrawn from therapy with these drugs, and the dosages adjusted as necessary. Patients should be monitored for the development of adverse effects.